| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| AMGN - Amgen Inc | BUY | 7,170 @ USD 338.36 | USD 2,426,041 | The ETF bought 7170 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 338.36 compared to the previous average buy price of 294.957. This is 14.7% higher than average price of previous purchases of AMGN. |
| VRTX - Vertex Pharmaceuticals Inc | BUY | 5,280 @ USD 433.15 | USD 2,287,032 | The ETF bought 5280 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 433.15 compared to the previous average buy price of 437.892. This is -1.1% lower than average price of previous purchases of VRTX. |
| GILD - Guild Esports Plc | BUY | 18,270 @ USD 123.91 | USD 2,263,836 | The ETF bought 18270 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 123.91 compared to the previous average buy price of 114.163. This is 8.5% higher than average price of previous purchases of GILD. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 2,580 @ USD 742 | USD 1,914,360 | The ETF bought 2580 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 742 compared to the previous average buy price of 637.295. This is 16.4% higher than average price of previous purchases of REGN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 3,240 @ USD 464.93 | USD 1,506,373 | The ETF bought 3240 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 464.93 compared to the previous average buy price of 369.392. This is 25.9% higher than average price of previous purchases of ALNY. |
| AZN - AstraZeneca PLC | BUY | 12,915 @ USD 90.17 | USD 1,164,546 | The ETF bought 12915 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 90.17 compared to the previous average buy price of 76.3004. This is 18.2% higher than average price of previous purchases of AZN. |
| INSM - Insmed Inc | BUY | 5,265 @ USD 206.6 | USD 1,087,749 | The ETF bought 5265 new shares of INSM (Insmed Inc). The shares were bought for an average price of 206.6 compared to the previous average buy price of 126.033. This is 63.9% higher than average price of previous purchases of INSM. |
| ARGX - argenx NV ADR | BUY | 765 @ USD 915.36 | USD 700,250 | The ETF bought 765 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 915.36 compared to the previous average buy price of 671.042. This is 36.4% higher than average price of previous purchases of ARGX. |
| BIIB - Biogen Inc | BUY | 3,660 @ USD 180.18 | USD 659,459 | The ETF bought 3660 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 180.18 compared to the previous average buy price of 142.319. This is 26.6% higher than average price of previous purchases of BIIB. |
| UTHR - United Therapeutics Corporation | BUY | 1,125 @ USD 474.14 | USD 533,408 | The ETF bought 1125 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 474.14 compared to the previous average buy price of 358.811. This is 32.1% higher than average price of previous purchases of UTHR. |
| INCY - Incyte Corporation | BUY | 4,875 @ USD 101.44 | USD 494,520 | The ETF bought 4875 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 101.44 compared to the previous average buy price of 77.1777. This is 31.4% higher than average price of previous purchases of INCY. |
| ILMN - Illumina Inc | BUY | 3,825 @ USD 127.55 | USD 487,879 | The ETF bought 3825 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 127.55 compared to the previous average buy price of 99.8955. This is 27.7% higher than average price of previous purchases of ILMN. |
| RPRX - Royalty Pharma Plc | BUY | 10,755 @ USD 39.53 | USD 425,145 | The ETF bought 10755 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 39.53 compared to the previous average buy price of 35.99. This is 9.8% higher than average price of previous purchases of RPRX. |
| MEDP - Medpace Holdings Inc | BUY | 705 @ USD 583.7 | USD 411,509 | The ETF bought 705 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 583.7 compared to the previous average buy price of 415.892. This is 40.3% higher than average price of previous purchases of MEDP. |
| NBIX - Neurocrine Biosciences Inc | BUY | 2,475 @ USD 152.48 | USD 377,388 | The ETF bought 2475 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 152.48 compared to the previous average buy price of 131.145. This is 16.3% higher than average price of previous purchases of NBIX. |
| RVMD - Revolution Medicines Inc | BUY | 4,680 @ USD 75.31 | USD 352,451 | The ETF bought 4680 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 75.31 compared to the previous average buy price of 44.5708. This is 69.0% higher than average price of previous purchases of RVMD. |
| BBIO - BridgeBio Pharma Inc | BUY | 4,785 @ USD 71.46 | USD 341,936 | The ETF bought 4785 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 71.46 compared to the previous average buy price of 47.1555. This is 51.5% higher than average price of previous purchases of BBIO. |
| ROIV - Roivant Sciences Ltd | BUY | 16,995 @ USD 20.1 | USD 341,600 | The ETF bought 16995 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 20.1 compared to the previous average buy price of 13.8219. This is 45.4% higher than average price of previous purchases of ROIV. |
| SNY - Sanofi ADR | BUY | 6,705 @ USD 49.85 | USD 334,244 | The ETF bought 6705 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 49.85 compared to the previous average buy price of 50.0812. This is -0.5% lower than average price of previous purchases of SNY. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 3,990 @ USD 81.31 | USD 324,427 | The ETF bought 3990 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 81.31 compared to the previous average buy price of 51.4289. This is 58.1% higher than average price of previous purchases of IONS. |
| GH - Guardant Health Inc | BUY | 3,120 @ USD 103.87 | USD 324,074 | The ETF bought 3120 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 103.87 compared to the previous average buy price of 60.3536. This is 72.1% higher than average price of previous purchases of GH. |
| SMMT - Summit Therapeutics PLC | BUY | 18,555 @ USD 17.25 | USD 320,074 | The ETF bought 18555 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 17.25 compared to the previous average buy price of 20.8641. This is -17.3% lower than average price of previous purchases of SMMT. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 555 @ USD 573.15 | USD 318,098 | The ETF bought 555 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 573.15 compared to the previous average buy price of 372.755. This is 53.8% higher than average price of previous purchases of MDGL. |
| VTRS - Viatris Inc | BUY | 29,175 @ USD 10.71 | USD 312,464 | The ETF bought 29175 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 10.71 compared to the previous average buy price of 9.70762. This is 10.3% higher than average price of previous purchases of VTRS. |
| ASND - Ascendis Pharma AS | BUY | 1,515 @ USD 202.16 | USD 306,272 | The ETF bought 1515 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 202.16 compared to the previous average buy price of 181.629. This is 11.3% higher than average price of previous purchases of ASND. |
| EXEL - Exelixis Inc | BUY | 6,705 @ USD 43.44 | USD 291,265 | The ETF bought 6705 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 43.44 compared to the previous average buy price of 41.2078. This is 5.4% higher than average price of previous purchases of EXEL. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 4,770 @ USD 53.89 | USD 257,055 | The ETF bought 4770 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 53.89 compared to the previous average buy price of 57.8786. This is -6.9% lower than average price of previous purchases of BMRN. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 1,515 @ USD 166.71 | USD 252,566 | The ETF bought 1515 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 166.71 compared to the previous average buy price of 127.982. This is 30.3% higher than average price of previous purchases of JAZZ. |
| BNTX - BioNTech SE | BUY | 2,505 @ USD 96.11 | USD 240,756 | The ETF bought 2505 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 96.11 compared to the previous average buy price of 104.7. This is -8.2% lower than average price of previous purchases of BNTX. |
| MRNA - Moderna Inc | BUY | 9,690 @ USD 24.06 | USD 233,141 | The ETF bought 9690 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 24.06 compared to the previous average buy price of 28.6235. This is -15.9% lower than average price of previous purchases of MRNA. |
| RNA - Avidity Biosciences Inc | BUY | 3,195 @ USD 71.54 | USD 228,570 | The ETF bought 3195 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 71.54 compared to the previous average buy price of 40.6951. This is 75.8% higher than average price of previous purchases of RNA. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 3,450 @ USD 57.95 | USD 199,928 | The ETF bought 3450 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 57.95 compared to the previous average buy price of 23.581. This is 145.7% higher than average price of previous purchases of ARWR. |
| HALO - Halozyme Therapeutics Inc | BUY | 2,910 @ USD 66.54 | USD 193,631 | The ETF bought 2910 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 66.54 compared to the previous average buy price of 61.0844. This is 8.9% higher than average price of previous purchases of HALO. |
| CYTK - Cytokinetics Inc | BUY | 2,970 @ USD 63.51 | USD 188,625 | The ETF bought 2970 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 63.51 compared to the previous average buy price of 45.4915. This is 39.6% higher than average price of previous purchases of CYTK. |
| MRUS - Merus BV | BUY | 1,890 @ USD 95.99 | USD 181,421 | The ETF bought 1890 new shares of MRUS (Merus BV). The shares were bought for an average price of 95.99 compared to the previous average buy price of 67.1721. This is 42.9% higher than average price of previous purchases of MRUS. |
| AXSM - Axsome Therapeutics Inc | BUY | 1,245 @ USD 142.09 | USD 176,902 | The ETF bought 1245 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 142.09 compared to the previous average buy price of 118.571. This is 19.8% higher than average price of previous purchases of AXSM. |
| NUVL - Nuvalent Inc | BUY | 1,665 @ USD 104.96 | USD 174,758 | The ETF bought 1665 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 104.96 compared to the previous average buy price of 84.7541. This is 23.8% higher than average price of previous purchases of NUVL. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 1,665 @ USD 101.39 | USD 168,814 | The ETF bought 1665 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 101.39 compared to the previous average buy price of 78.6253. This is 29.0% higher than average price of previous purchases of RYTM. |
| PTCT - PTC Therapeutics Inc | BUY | 1,980 @ USD 78.495 | USD 155,420 | The ETF bought 1980 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 78.495 compared to the previous average buy price of 57.5526. This is 36.4% higher than average price of previous purchases of PTCT. |
| KRYS - Krystal Biotech Inc | BUY | 720 @ USD 215.06 | USD 154,843 | The ETF bought 720 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 215.06 compared to the previous average buy price of 166.365. This is 29.3% higher than average price of previous purchases of KRYS. |
| PCVX - Vaxcyte Inc | BUY | 3,240 @ USD 44.7 | USD 144,828 | The ETF bought 3240 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 44.7 compared to the previous average buy price of 45.2623. This is -1.2% lower than average price of previous purchases of PCVX. |
| COGT - Cogent Biosciences Inc | BUY | 3,450 @ USD 38.98 | USD 134,481 | The ETF bought 3450 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 38.98 compared to the previous average buy price of 13.3794. This is 191.3% higher than average price of previous purchases of COGT. |
| PTGX - Protagonist Therapeutics Inc | BUY | 1,560 @ USD 84.65 | USD 132,054 | The ETF bought 1560 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 84.65 compared to the previous average buy price of 59.7808. This is 41.6% higher than average price of previous purchases of PTGX. |
| ALKS - Alkermes Plc | BUY | 4,125 @ USD 28.97 | USD 119,501 | The ETF bought 4125 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 28.97 compared to the previous average buy price of 30.3001. This is -4.4% lower than average price of previous purchases of ALKS. |
| CRSP - Crispr Therapeutics AG | BUY | 2,265 @ USD 51.58 | USD 116,829 | The ETF bought 2265 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 51.58 compared to the previous average buy price of 52.4756. This is -1.7% lower than average price of previous purchases of CRSP. |
| ADMA - ADMA Biologics Inc | BUY | 6,000 @ USD 19.25 | USD 115,500 | The ETF bought 6000 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 19.25 compared to the previous average buy price of 17.3702. This is 10.8% higher than average price of previous purchases of ADMA. |
| KYMR - Kymera Therapeutics Inc | BUY | 1,785 @ USD 64.27 | USD 114,722 | The ETF bought 1785 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 64.27 compared to the previous average buy price of 48.3482. This is 32.9% higher than average price of previous purchases of KYMR. |
| AKRO - Akero Therapeutics Inc | BUY | 1,995 @ USD 54.49 | USD 108,708 | The ETF bought 1995 new shares of AKRO (Akero Therapeutics Inc). The shares were bought for an average price of 54.49 compared to the previous average buy price of 49.768. This is 9.5% higher than average price of previous purchases of AKRO. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 4,245 @ USD 25.43 | USD 107,950 | The ETF bought 4245 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 25.43 compared to the previous average buy price of 21.1984. This is 20.0% higher than average price of previous purchases of ACAD. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 2,355 @ USD 45.01 | USD 105,999 | The ETF bought 2355 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 45.01 compared to the previous average buy price of 35.9832. This is 25.1% higher than average price of previous purchases of CRNX. |
| SRRK - Scholar Rock Holding Corp | BUY | 2,415 @ USD 41.08 | USD 99,208 | The ETF bought 2415 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 41.08 compared to the previous average buy price of 35.5005. This is 15.7% higher than average price of previous purchases of SRRK. |
| IMVT - Immunovant Inc | BUY | 4,395 @ USD 22.02 | USD 96,778 | The ETF bought 4395 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 22.02 compared to the previous average buy price of 18.5525. This is 18.7% higher than average price of previous purchases of IMVT. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 495 @ USD 195.1 | USD 96,575 | The ETF bought 495 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 195.1 compared to the previous average buy price of 140.751. This is 38.6% higher than average price of previous purchases of LGND. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 7,920 @ USD 12 | USD 95,040 | The ETF bought 7920 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 12 compared to the previous average buy price of 9.16066. This is 31.0% higher than average price of previous purchases of AMRX. |
| ACLX - Arcellx Inc | BUY | 1,380 @ USD 68.81 | USD 94,958 | The ETF bought 1380 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 68.81 compared to the previous average buy price of 72.9556. This is -5.7% lower than average price of previous purchases of ACLX. |
| PRAX - Praxis Precision Medicines Inc | BUY | 525 @ USD 179.115 | USD 94,035 | The ETF bought 525 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 179.115 compared to the previous average buy price of 74.6871. This is 139.8% higher than average price of previous purchases of PRAX. |
| VCYT - Veracyte Inc | BUY | 1,980 @ USD 46.16 | USD 91,397 | The ETF bought 1980 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 46.16 compared to the previous average buy price of 32.6773. This is 41.3% higher than average price of previous purchases of VCYT. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 1,260 @ USD 69.88 | USD 88,049 | The ETF bought 1260 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 69.88 compared to the previous average buy price of 57.2579. This is 22.0% higher than average price of previous purchases of MIRM. |
| GRAL - GRAIL, LLC | BUY | 900 @ USD 97.38 | USD 87,642 | The ETF bought 900 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 97.38 compared to the previous average buy price of 57.1545. This is 70.4% higher than average price of previous purchases of GRAL. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 2,970 @ USD 29.43 | USD 87,407 | The ETF bought 2970 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 29.43 compared to the previous average buy price of 17.6042. This is 67.2% higher than average price of previous purchases of ARQT. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 1,065 @ USD 79.44 | USD 84,604 | The ETF bought 1065 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 79.44 compared to the previous average buy price of 52.1302. This is 52.4% higher than average price of previous purchases of TARS. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 1,935 @ USD 42.88 | USD 82,973 | The ETF bought 1935 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 42.88 compared to the previous average buy price of 36.3729. This is 17.9% higher than average price of previous purchases of XENE. |
| RARE - Ultragenyx | BUY | 2,430 @ USD 33.47 | USD 81,332 | The ETF bought 2430 new shares of RARE (Ultragenyx). The shares were bought for an average price of 33.47 compared to the previous average buy price of 36.1308. This is -7.4% lower than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 2,430 @ USD 33.47 | USD 81,332 | The ETF bought 2430 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 33.47 compared to the previous average buy price of 36.1308. This is -7.4% lower than average price of previous purchases of RARE. |
| CGON - CG Oncology, Inc. Common stock | BUY | 1,920 @ USD 41.37 | USD 79,430 | The ETF bought 1920 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 41.37 compared to the previous average buy price of 31.2827. This is 32.2% higher than average price of previous purchases of CGON. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 1,140 @ USD 69.13 | USD 78,808 | The ETF bought 1140 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 69.13 compared to the previous average buy price of 46.4432. This is 48.8% higher than average price of previous purchases of APGE. |
| IRON - Ironveld Plc | BUY | 870 @ USD 89.72 | USD 78,056 | The ETF bought 870 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 89.72 compared to the previous average buy price of 61.7251. This is 45.4% higher than average price of previous purchases of IRON. |
| TVTX - Travere Therapeutics Inc | BUY | 2,205 @ USD 33.99 | USD 74,948 | The ETF bought 2205 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 33.99 compared to the previous average buy price of 21.514. This is 58.0% higher than average price of previous purchases of TVTX. |
| IDYA - Ideaya Biosciences Inc | BUY | 2,220 @ USD 33.69 | USD 74,792 | The ETF bought 2220 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 33.69 compared to the previous average buy price of 24.465. This is 37.7% higher than average price of previous purchases of IDYA. |
| FOLD - Amicus Therapeutics Inc | BUY | 7,650 @ USD 9.73 | USD 74,435 | The ETF bought 7650 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 9.73 compared to the previous average buy price of 7.63025. This is 27.5% higher than average price of previous purchases of FOLD. |
| DYN - Dyne Therapeutics Inc | BUY | 3,585 @ USD 19.99 | USD 71,664 | The ETF bought 3585 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 19.99 compared to the previous average buy price of 13.694. This is 46.0% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 3,585 @ USD 19.99 | USD 71,664 | The ETF bought 3585 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 19.99 compared to the previous average buy price of 13.694. This is 46.0% higher than average price of previous purchases of DYN. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 3,780 @ USD 18.69 | USD 70,648 | The ETF bought 3780 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 18.69 compared to the previous average buy price of 12.4532. This is 50.1% higher than average price of previous purchases of ADPT. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 2,370 @ USD 28.51 | USD 67,569 | The ETF bought 2370 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 28.51 compared to the previous average buy price of 17.5392. This is 62.6% higher than average price of previous purchases of CNTA. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 3,180 @ USD 20.66 | USD 65,699 | The ETF bought 3180 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 20.66 compared to the previous average buy price of 21.0201. This is -1.7% lower than average price of previous purchases of APLS. |
| DNLI - Denali Therapeutics Inc | BUY | 3,630 @ USD 17.84 | USD 64,759 | The ETF bought 3630 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 17.84 compared to the previous average buy price of 15.5149. This is 15.0% higher than average price of previous purchases of DNLI. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 1,635 @ USD 39.15 | USD 64,010 | The ETF bought 1635 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 39.15 compared to the previous average buy price of 21.7179. This is 80.3% higher than average price of previous purchases of MLYS. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 1,410 @ USD 44.12 | USD 62,209 | The ETF bought 1410 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 44.12 compared to the previous average buy price of 38.4653. This is 14.7% higher than average price of previous purchases of SUPN. |
| EWTX - Edgewise Therapeutics Inc | BUY | 2,610 @ USD 22.98 | USD 59,978 | The ETF bought 2610 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 22.98 compared to the previous average buy price of 16.6529. This is 38.0% higher than average price of previous purchases of EWTX. |
| VERA - Vera Therapeutics Inc | BUY | 1,575 @ USD 37.25 | USD 58,669 | The ETF bought 1575 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 37.25 compared to the previous average buy price of 27.2684. This is 36.6% higher than average price of previous purchases of VERA. |
| BEAM - Beam Therapeutics Inc | BUY | 2,505 @ USD 23.37 | USD 58,542 | The ETF bought 2505 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 23.37 compared to the previous average buy price of 20.8217. This is 12.2% higher than average price of previous purchases of BEAM. |
| TERN - Tern Plc | BUY | 2,175 @ USD 25.79 | USD 56,093 | The ETF bought 2175 new shares of TERN (Tern Plc). The shares were bought for an average price of 25.79 compared to the previous average buy price of 7.38429. This is 249.3% higher than average price of previous purchases of TERN. |
| LEGN - Legend Biotech Corp | BUY | 2,100 @ USD 26.69 | USD 56,049 | The ETF bought 2100 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 26.69 compared to the previous average buy price of 33.9086. This is -21.3% lower than average price of previous purchases of LEGN. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 3,270 @ USD 15.91 | USD 52,026 | The ETF bought 3270 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 15.91 compared to the previous average buy price of 9.96065. This is 59.7% higher than average price of previous purchases of AUPH. |
| AVDL - Avadel Pharmaceuticals PLC | BUY | 2,415 @ USD 21.35 | USD 51,560 | The ETF bought 2415 new shares of AVDL (Avadel Pharmaceuticals PLC). The shares were bought for an average price of 21.35 compared to the previous average buy price of 12.1748. This is 75.4% higher than average price of previous purchases of AVDL. |
| TXG - 10X Genomics Inc | BUY | 2,865 @ USD 17.94 | USD 51,398 | The ETF bought 2865 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 17.94 compared to the previous average buy price of 12.6558. This is 41.8% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 2,865 @ USD 17.94 | USD 51,398 | The ETF bought 2865 new shares of TXG (Terex Corporation). The shares were bought for an average price of 17.94 compared to the previous average buy price of 12.6558. This is 41.8% higher than average price of previous purchases of TXG. |
| HRMY - Harmony Biosciences Holdings | BUY | 1,425 @ USD 36.01 | USD 51,314 | The ETF bought 1425 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 36.01 compared to the previous average buy price of 32.0766. This is 12.3% higher than average price of previous purchases of HRMY. |
| IBRX - Immunitybio Inc | BUY | 23,835 @ USD 2.09 | USD 49,815 | The ETF bought 23835 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 2.09 compared to the previous average buy price of 2.70555. This is -22.8% lower than average price of previous purchases of IBRX. |
| SRPT - Sarepta Therapeutics Inc | BUY | 2,430 @ USD 20.47 | USD 49,742 | The ETF bought 2430 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 20.47 compared to the previous average buy price of 32.7195. This is -37.4% lower than average price of previous purchases of SRPT. |
| OCUL - Ocular Therapeutix Inc | BUY | 4,320 @ USD 11.25 | USD 48,600 | The ETF bought 4320 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 11.25 compared to the previous average buy price of 9.91088. This is 13.5% higher than average price of previous purchases of OCUL. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 1,920 @ USD 25.1 | USD 48,192 | The ETF bought 1920 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 25.1 compared to the previous average buy price of 15.5176. This is 61.8% higher than average price of previous purchases of ZYME. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 1,470 @ USD 32.12 | USD 47,216 | The ETF bought 1470 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 32.12 compared to the previous average buy price of 24.5049. This is 31.1% higher than average price of previous purchases of GPCR. |
| VCEL - Vericel Corp Ord | BUY | 1,245 @ USD 37.65 | USD 46,874 | The ETF bought 1245 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 37.65 compared to the previous average buy price of 40.7522. This is -7.6% lower than average price of previous purchases of VCEL. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 10,830 @ USD 4.32 | USD 46,786 | The ETF bought 10830 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.32 compared to the previous average buy price of 5.65015. This is -23.5% lower than average price of previous purchases of RXRX. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 1,680 @ USD 27.15 | USD 45,612 | The ETF bought 1680 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 27.15 compared to the previous average buy price of 7.00422. This is 287.6% higher than average price of previous purchases of OLMA. |
| TWST - Twist Bioscience Corp | BUY | 1,500 @ USD 29.7 | USD 44,550 | The ETF bought 1500 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 29.7 compared to the previous average buy price of 35.5067. This is -16.4% lower than average price of previous purchases of TWST. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 540 @ USD 82.12 | USD 44,345 | The ETF bought 540 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 82.12 compared to the previous average buy price of 73.7505. This is 11.3% higher than average price of previous purchases of ANIP. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 1,095 @ USD 40.07 | USD 43,877 | The ETF bought 1095 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 40.07 compared to the previous average buy price of 31.1472. This is 28.6% higher than average price of previous purchases of KNSA. |
| MNKD - MannKind Corp | BUY | 7,650 @ USD 5.59 | USD 42,764 | The ETF bought 7650 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.59 compared to the previous average buy price of 4.78726. This is 16.8% higher than average price of previous purchases of MNKD. |
| SYRE - Spyre Therapeutics Inc. | BUY | 1,485 @ USD 28.4 | USD 42,174 | The ETF bought 1485 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 28.4 compared to the previous average buy price of 18.4807. This is 53.7% higher than average price of previous purchases of SYRE. |
| STOK - Stoke Therapeutics Inc | BUY | 1,395 @ USD 29.81 | USD 41,585 | The ETF bought 1395 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 29.81 compared to the previous average buy price of 17.3645. This is 71.7% higher than average price of previous purchases of STOK. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 2,145 @ USD 18.79 | USD 40,305 | The ETF bought 2145 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 18.79 compared to the previous average buy price of 12.4207. This is 51.3% higher than average price of previous purchases of SNDX. |
| AGIO - Agios Pharm | BUY | 1,440 @ USD 26.98 | USD 38,851 | The ETF bought 1440 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 26.98 compared to the previous average buy price of 35.8927. This is -24.8% lower than average price of previous purchases of AGIO. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 5,235 @ USD 7.16 | USD 37,483 | The ETF bought 5235 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 7.16 compared to the previous average buy price of 8.17729. This is -12.4% lower than average price of previous purchases of BCRX. |
| COLL - Collegium Pharmaceutical Inc | BUY | 780 @ USD 47.51 | USD 37,058 | The ETF bought 780 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 47.51 compared to the previous average buy price of 33.1567. This is 43.3% higher than average price of previous purchases of COLL. |
| IMCR - Immunocore Holdings Ltd | BUY | 1,020 @ USD 36.17 | USD 36,893 | The ETF bought 1020 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 36.17 compared to the previous average buy price of 33.3971. This is 8.3% higher than average price of previous purchases of IMCR. |
| HROW - Harrow Health Inc | BUY | 915 @ USD 40.17 | USD 36,756 | The ETF bought 915 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 40.17 compared to the previous average buy price of 34.1208. This is 17.7% higher than average price of previous purchases of HROW. |
| QURE - Uniqure NV | BUY | 1,380 @ USD 25.32 | USD 34,942 | The ETF bought 1380 new shares of QURE (Uniqure NV). The shares were bought for an average price of 25.32 compared to the previous average buy price of 23.6699. This is 7.0% higher than average price of previous purchases of QURE. |
| ARDX - Ardelyx Inc | BUY | 6,030 @ USD 5.54 | USD 33,406 | The ETF bought 6030 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 5.54 compared to the previous average buy price of 4.74565. This is 16.7% higher than average price of previous purchases of ARDX. |
| NRIX - Nurix Therapeutics Inc | BUY | 2,010 @ USD 16.35 | USD 32,864 | The ETF bought 2010 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 16.35 compared to the previous average buy price of 12.3672. This is 32.2% higher than average price of previous purchases of NRIX. |
| GMAB - Genmab AS | BUY | 1,035 @ USD 31.71 | USD 32,820 | The ETF bought 1035 new shares of GMAB (Genmab AS). The shares were bought for an average price of 31.71 compared to the previous average buy price of 24.2389. This is 30.8% higher than average price of previous purchases of GMAB. |
| INVA - Innoviva Inc | BUY | 1,560 @ USD 20.98 | USD 32,729 | The ETF bought 1560 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 20.98 compared to the previous average buy price of 19.2492. This is 9.0% higher than average price of previous purchases of INVA. |
| RLAY - Relay Therapeutics Inc | BUY | 4,305 @ USD 7.49 | USD 32,244 | The ETF bought 4305 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 7.49 compared to the previous average buy price of 4.42378. This is 69.3% higher than average price of previous purchases of RLAY. |
| DVAX - Dynavax Technologies Corporation | BUY | 2,925 @ USD 10.88 | USD 31,824 | The ETF bought 2925 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 10.88 compared to the previous average buy price of 10.5525. This is 3.1% higher than average price of previous purchases of DVAX. |
| AMPH - Amphastar P | BUY | 1,155 @ USD 26.67 | USD 30,804 | The ETF bought 1155 new shares of AMPH (Amphastar P). The shares were bought for an average price of 26.67 compared to the previous average buy price of 25.729. This is 3.7% higher than average price of previous purchases of AMPH. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 2,220 @ USD 13.75 | USD 30,525 | The ETF bought 2220 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 13.75 compared to the previous average buy price of 7.53725. This is 82.4% higher than average price of previous purchases of AMLX. |
| NVCR - Novocure Ltd | BUY | 2,790 @ USD 10.92 | USD 30,467 | The ETF bought 2790 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 10.92 compared to the previous average buy price of 16.2889. This is -33.0% lower than average price of previous purchases of NVCR. |
| ELVN - Enliven Therapeutics Inc. | BUY | 1,470 @ USD 20.56 | USD 30,223 | The ETF bought 1470 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 20.56 compared to the previous average buy price of 20.9678. This is -1.9% lower than average price of previous purchases of ELVN. |
| URGN - UroGen Pharma Ltd | BUY | 1,185 @ USD 24.38 | USD 28,890 | The ETF bought 1185 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 24.38 compared to the previous average buy price of 15.6874. This is 55.4% higher than average price of previous purchases of URGN. |
| FTRE - Fortrea Holdings Inc. | BUY | 2,265 @ USD 12.75 | USD 28,879 | The ETF bought 2265 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 12.75 compared to the previous average buy price of 7.23634. This is 76.2% higher than average price of previous purchases of FTRE. |
| XNCR - Xencor Inc | BUY | 1,785 @ USD 15.99 | USD 28,542 | The ETF bought 1785 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 15.99 compared to the previous average buy price of 11.7195. This is 36.4% higher than average price of previous purchases of XNCR. |
| WVE - Wave Life Sciences Ltd | BUY | 4,080 @ USD 6.99 | USD 28,519 | The ETF bought 4080 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 6.99 compared to the previous average buy price of 8.33939. This is -16.2% lower than average price of previous purchases of WVE. |
| ANAB - AnaptysBio Inc | BUY | 690 @ USD 40.9 | USD 28,221 | The ETF bought 690 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 40.9 compared to the previous average buy price of 25.6035. This is 59.7% higher than average price of previous purchases of ANAB. |
| CSTL - Castle Biosciences Inc | BUY | 720 @ USD 39.1 | USD 28,152 | The ETF bought 720 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 39.1 compared to the previous average buy price of 23.4814. This is 66.5% higher than average price of previous purchases of CSTL. |
| TNGX - Tango Therapeutics Inc | BUY | 2,775 @ USD 10.08 | USD 27,972 | The ETF bought 2775 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 10.08 compared to the previous average buy price of 6.59383. This is 52.9% higher than average price of previous purchases of TNGX. |
| TSHA - Taysha Gene Therapies Inc | BUY | 6,825 @ USD 4.06 | USD 27,709 | The ETF bought 6825 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 4.06 compared to the previous average buy price of 3.01401. This is 34.7% higher than average price of previous purchases of TSHA. |
| PCRX - Pacira BioSciences, Inc. | BUY | 1,125 @ USD 24.07 | USD 27,079 | The ETF bought 1125 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 24.07 compared to the previous average buy price of 23.8401. This is 1.0% higher than average price of previous purchases of PCRX. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 4,170 @ USD 6.47 | USD 26,980 | The ETF bought 4170 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 6.47 compared to the previous average buy price of 6.17393. This is 4.8% higher than average price of previous purchases of XERS. |
| NVAX - Novavax Inc | BUY | 4,065 @ USD 6.6 | USD 26,829 | The ETF bought 4065 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 6.6 compared to the previous average buy price of 7.32717. This is -9.9% lower than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 4,065 @ USD 6.6 | USD 26,829 | The ETF bought 4065 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 6.6 compared to the previous average buy price of 7.32717. This is -9.9% lower than average price of previous purchases of NVAX. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 1,815 @ USD 14.74 | USD 26,753 | The ETF bought 1815 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 14.74 compared to the previous average buy price of 9.65184. This is 52.7% higher than average price of previous purchases of PHAT. |
| PGEN - Precigen Inc | BUY | 7,635 @ USD 3.48 | USD 26,570 | The ETF bought 7635 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 3.48 compared to the previous average buy price of 2.50865. This is 38.7% higher than average price of previous purchases of PGEN. |
| SANA - Sana Biotechnology Inc | BUY | 6,585 @ USD 3.97 | USD 26,142 | The ETF bought 6585 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 3.97 compared to the previous average buy price of 3.21629. This is 23.4% higher than average price of previous purchases of SANA. |
| GRFS - Grifols SA ADR | BUY | 3,060 @ USD 8.50999 | USD 26,041 | The ETF bought 3060 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 8.50999 compared to the previous average buy price of 9.2871. This is -8.4% lower than average price of previous purchases of GRFS. |
| ABCL - Abcellera Biologics Inc | BUY | 7,500 @ USD 3.46 | USD 25,950 | The ETF bought 7500 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 3.46 compared to the previous average buy price of 3.88089. This is -10.8% lower than average price of previous purchases of ABCL. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 2,430 @ USD 10.65 | USD 25,880 | The ETF bought 2430 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 10.65 compared to the previous average buy price of 10.6637. This is -0.1% lower than average price of previous purchases of ORIC. |
| KURA - Kura Oncology Inc | BUY | 2,265 @ USD 11.13 | USD 25,209 | The ETF bought 2265 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 11.13 compared to the previous average buy price of 7.6868. This is 44.8% higher than average price of previous purchases of KURA. |
| SVRA - Savara Inc | BUY | 4,320 @ USD 5.81 | USD 25,099 | The ETF bought 4320 new shares of SVRA (Savara Inc). The shares were bought for an average price of 5.81 compared to the previous average buy price of 3.07593. This is 88.9% higher than average price of previous purchases of SVRA. |
| EYPT - Eyepoint Pharmaceuticals Inc | BUY | 1,725 @ USD 13.69 | USD 23,615 | The ETF bought 1725 new shares of EYPT (Eyepoint Pharmaceuticals Inc). The shares were bought for an average price of 13.69 compared to the previous average buy price of 9.21692. This is 48.5% higher than average price of previous purchases of EYPT. |
| ZLAB - Zai Lab Ltd | BUY | 1,200 @ USD 19.52 | USD 23,424 | The ETF bought 1200 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 19.52 compared to the previous average buy price of 32.8402. This is -40.6% lower than average price of previous purchases of ZLAB. |
| MNMD - Mind Medicine Inc | BUY | 1,935 @ USD 12.06 | USD 23,336 | The ETF bought 1935 new shares of MNMD (Mind Medicine Inc). The shares were bought for an average price of 12.06 compared to the previous average buy price of 8.92109. This is 35.2% higher than average price of previous purchases of MNMD. |
| TBPH - Theravance Biopharma Inc | BUY | 1,260 @ USD 18.43 | USD 23,222 | The ETF bought 1260 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 18.43 compared to the previous average buy price of 12.5117. This is 47.3% higher than average price of previous purchases of TBPH. |
| SPRY - Silverback Therapeutics Inc | BUY | 2,460 @ USD 9.04 | USD 22,238 | The ETF bought 2460 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 9.04 compared to the previous average buy price of 13.0567. This is -30.8% lower than average price of previous purchases of SPRY. |
| NTLA - Intellia Therapeutics Inc | BUY | 2,730 @ USD 8.09999 | USD 22,113 | The ETF bought 2730 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 8.09999 compared to the previous average buy price of 12.0017. This is -32.5% lower than average price of previous purchases of NTLA. |
| ERAS - Erasca Inc | BUY | 7,635 @ USD 2.89 | USD 22,065 | The ETF bought 7635 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 2.89 compared to the previous average buy price of 1.79857. This is 60.7% higher than average price of previous purchases of ERAS. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 2,550 @ USD 8.43001 | USD 21,497 | The ETF bought 2550 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 8.43001 compared to the previous average buy price of 7.60142. This is 10.9% higher than average price of previous purchases of DAWN. |
| ARVN - Arvinas Inc | BUY | 1,800 @ USD 11.66 | USD 20,988 | The ETF bought 1800 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 11.66 compared to the previous average buy price of 9.09454. This is 28.2% higher than average price of previous purchases of ARVN. |
| ABUS - Arbutus Biopharma Corp | BUY | 4,920 @ USD 4.17 | USD 20,516 | The ETF bought 4920 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.17 compared to the previous average buy price of 3.73412. This is 11.7% higher than average price of previous purchases of ABUS. |
| PAHC - Phibro Animal Health Corporation | BUY | 495 @ USD 40.68 | USD 20,137 | The ETF bought 495 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 40.68 compared to the previous average buy price of 29.8607. This is 36.2% higher than average price of previous purchases of PAHC. |
| REPL - Replimune Group Inc | BUY | 2,010 @ USD 10 | USD 20,100 | The ETF bought 2010 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 10 compared to the previous average buy price of 8.97434. This is 11.4% higher than average price of previous purchases of REPL. |
| GERN - Geron Corporation | BUY | 15,960 @ USD 1.23 | USD 19,631 | The ETF bought 15960 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.23 compared to the previous average buy price of 1.48342. This is -17.1% lower than average price of previous purchases of GERN. |
| VIR - Vir Biotechnology Inc | BUY | 3,465 @ USD 5.63 | USD 19,508 | The ETF bought 3465 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 5.63 compared to the previous average buy price of 5.85367. This is -3.8% lower than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 3,465 @ USD 5.63 | USD 19,508 | The ETF bought 3465 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 5.63 compared to the previous average buy price of 5.85367. This is -3.8% lower than average price of previous purchases of VIR. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 8,955 @ USD 2.135 | USD 19,119 | The ETF bought 8955 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2.135 compared to the previous average buy price of 2.43743. This is -12.4% lower than average price of previous purchases of IOVA. |
| PACB - Pacific Biosciences of California | BUY | 8,010 @ USD 2.32 | USD 18,583 | The ETF bought 8010 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 2.32 compared to the previous average buy price of 1.60005. This is 45.0% higher than average price of previous purchases of PACB. |
| KROS - Keros Therapeutics Inc | BUY | 1,005 @ USD 16.83 | USD 16,914 | The ETF bought 1005 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 16.83 compared to the previous average buy price of 14.1183. This is 19.2% higher than average price of previous purchases of KROS. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 1,230 @ USD 13.52 | USD 16,630 | The ETF bought 1230 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 13.52 compared to the previous average buy price of 12.4371. This is 8.7% higher than average price of previous purchases of KALV. |
| RGNX - Regenxbio Inc | BUY | 1,320 @ USD 12.21 | USD 16,117 | The ETF bought 1320 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 12.21 compared to the previous average buy price of 9.49627. This is 28.6% higher than average price of previous purchases of RGNX. |
| MGTX - MeiraGTx Holdings PLC | BUY | 2,040 @ USD 7.75 | USD 15,810 | The ETF bought 2040 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 7.75 compared to the previous average buy price of 7.247. This is 6.9% higher than average price of previous purchases of MGTX. |
| CGEM - Cullinan Oncology LLC | BUY | 1,545 @ USD 10.2 | USD 15,759 | The ETF bought 1545 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 10.2 compared to the previous average buy price of 8.13906. This is 25.3% higher than average price of previous purchases of CGEM. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 4,440 @ USD 3.3 | USD 14,652 | The ETF bought 4440 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 3.3 compared to the previous average buy price of 3.92776. This is -16.0% lower than average price of previous purchases of PRME. |
| PRTA - Prothena Corporation plc | BUY | 1,395 @ USD 10.35 | USD 14,438 | The ETF bought 1395 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 10.35 compared to the previous average buy price of 9.21844. This is 12.3% higher than average price of previous purchases of PRTA. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 3,975 @ USD 3.44 | USD 13,674 | The ETF bought 3975 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.44 compared to the previous average buy price of 2.8028. This is 22.7% higher than average price of previous purchases of MRVI. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 3,885 @ USD 3.5 | USD 13,598 | The ETF bought 3885 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 3.5 compared to the previous average buy price of 1.46201. This is 139.4% higher than average price of previous purchases of IRWD. |
| LXRX - Lexicon Pharmaceuticals Inc | BUY | 9,645 @ USD 1.34 | USD 12,924 | The ETF bought 9645 new shares of LXRX (Lexicon Pharmaceuticals Inc). The shares were bought for an average price of 1.34 compared to the previous average buy price of 1.10323. This is 21.5% higher than average price of previous purchases of LXRX. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 1,275 @ USD 10.13 | USD 12,916 | The ETF bought 1275 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 10.13 compared to the previous average buy price of 6.97773. This is 45.2% higher than average price of previous purchases of FDMT. |
| GLPG - Galapagos NV ADR | BUY | 375 @ USD 31.35 | USD 11,756 | The ETF bought 375 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 31.35 compared to the previous average buy price of 29.246. This is 7.2% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 375 @ USD 31.35 | USD 11,756 | The ETF bought 375 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 31.35 compared to the previous average buy price of 29.246. This is 7.2% higher than average price of previous purchases of GLPG. |
| EOLS - Evolus Inc | BUY | 1,785 @ USD 6.52 | USD 11,638 | The ETF bought 1785 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 6.52 compared to the previous average buy price of 8.96695. This is -27.3% lower than average price of previous purchases of EOLS. |
| HCM - HUTCHMED China Ltd | BUY | 810 @ USD 14.26 | USD 11,551 | The ETF bought 810 new shares of HCM (HUTCHMED China Ltd). The shares were bought for an average price of 14.26 compared to the previous average buy price of 15.3207. This is -6.9% lower than average price of previous purchases of HCM. |
| HCM - Hitachi Construction Machinery Co. Ltd | BUY | 810 @ USD 14.26 | USD 11,551 | The ETF bought 810 new shares of HCM (Hitachi Construction Machinery Co. Ltd). The shares were bought for an average price of 14.26 compared to the previous average buy price of 15.3207. This is -6.9% lower than average price of previous purchases of HCM. |
| SIGA - SIGA Technologies Inc | BUY | 1,800 @ USD 5.93 | USD 10,674 | The ETF bought 1800 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 5.93 compared to the previous average buy price of 6.72497. This is -11.8% lower than average price of previous purchases of SIGA. |
| ALT - Altitude Group Plc | BUY | 2,175 @ USD 4.76001 | USD 10,353 | The ETF bought 2175 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 4.76001 compared to the previous average buy price of 5.22042. This is -8.8% lower than average price of previous purchases of ALT. |
| TRDA - Entrada Therapeutics Inc | BUY | 1,050 @ USD 9.85 | USD 10,343 | The ETF bought 1050 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 9.85 compared to the previous average buy price of 7.8564. This is 25.4% higher than average price of previous purchases of TRDA. |
| LYEL - Lyell Immunopharma Inc | BUY | 480 @ USD 20.81 | USD 9,989 | The ETF bought 480 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 20.81 compared to the previous average buy price of 5.05806. This is 311.4% higher than average price of previous purchases of LYEL. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 2,760 @ USD 3.09001 | USD 8,528 | The ETF bought 2760 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.09001 compared to the previous average buy price of 4.96621. This is -37.8% lower than average price of previous purchases of RCKT. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 1,215 @ USD 6.86999 | USD 8,347 | The ETF bought 1215 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 6.86999 compared to the previous average buy price of 8.3822. This is -18.0% lower than average price of previous purchases of BCYC. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 1,665 @ USD 4.92001 | USD 8,192 | The ETF bought 1665 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 4.92001 compared to the previous average buy price of 4.86977. This is 1.0% higher than average price of previous purchases of VNDA. |
| AVXL - Anavex Life Sciences Corp | BUY | 2,220 @ USD 3.66999 | USD 8,147 | The ETF bought 2220 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 3.66999 compared to the previous average buy price of 8.85087. This is -58.5% lower than average price of previous purchases of AVXL. |
| ALLO - Allogene Therapeutics Inc | BUY | 5,700 @ USD 1.34 | USD 7,638 | The ETF bought 5700 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.34 compared to the previous average buy price of 1.33614. This is 0.3% higher than average price of previous purchases of ALLO. |
| AUTL - Autolus Therapeutics Ltd | BUY | 5,640 @ USD 1.34 | USD 7,558 | The ETF bought 5640 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.34 compared to the previous average buy price of 1.78057. This is -24.7% lower than average price of previous purchases of AUTL. |
| ACIU - AC Immune Ltd | BUY | 2,595 @ USD 2.76999 | USD 7,188 | The ETF bought 2595 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 2.76999 compared to the previous average buy price of 2.49387. This is 11.1% higher than average price of previous purchases of ACIU. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 2,160 @ USD 3 | USD 6,480 | The ETF bought 2160 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 3 compared to the previous average buy price of 3.28775. This is -8.8% lower than average price of previous purchases of AVIR. |
| OABI - OmniAb Inc. | BUY | 3,210 @ USD 1.71 | USD 5,489 | The ETF bought 3210 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 1.71 compared to the previous average buy price of 1.88515. This is -9.3% lower than average price of previous purchases of OABI. |
| HUMA - Humacyte Inc | BUY | 4,230 @ USD 1.26 | USD 5,330 | The ETF bought 4230 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 1.26 compared to the previous average buy price of 2.11992. This is -40.6% lower than average price of previous purchases of HUMA. |
| EDIT - Editas Medicine Inc | BUY | 2,475 @ USD 2.11001 | USD 5,222 | The ETF bought 2475 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 2.11001 compared to the previous average buy price of 2.7078. This is -22.1% lower than average price of previous purchases of EDIT. |
| VYGR - Voyager Therapeutics Inc | BUY | 1,335 @ USD 3.77001 | USD 5,033 | The ETF bought 1335 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 3.77001 compared to the previous average buy price of 3.89641. This is -3.2% lower than average price of previous purchases of VYGR. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 735 @ USD 6.25001 | USD 4,594 | The ETF bought 735 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 6.25001 compared to the previous average buy price of 13.8178. This is -54.8% lower than average price of previous purchases of ARCT. |
| MXCT - MaxCyte Inc | BUY | 2,775 @ USD 1.56999 | USD 4,357 | The ETF bought 2775 new shares of MXCT (MaxCyte Inc). The shares were bought for an average price of 1.56999 compared to the previous average buy price of 2.11655. This is -25.8% lower than average price of previous purchases of MXCT. |
| MRSN - Mersana Therapeutics Inc | BUY | 120 @ USD 27.5201 | USD 3,302 | The ETF bought 120 new shares of MRSN (Mersana Therapeutics Inc). The shares were bought for an average price of 27.5201 compared to the previous average buy price of 0.803828. This is 3,323.6% higher than average price of previous purchases of MRSN. |
| ALEC - Alector Inc | BUY | 2,760 @ USD 1.14001 | USD 3,146 | The ETF bought 2760 new shares of ALEC (Alector Inc). The shares were bought for an average price of 1.14001 compared to the previous average buy price of 1.85165. This is -38.4% lower than average price of previous purchases of ALEC. |
| FATE - Fate Therapeutics Inc | BUY | 2,835 @ USD 1.005 | USD 2,849 | The ETF bought 2835 new shares of FATE (Fate Therapeutics Inc). The shares were bought for an average price of 1.005 compared to the previous average buy price of 1.1718. This is -14.2% lower than average price of previous purchases of FATE. |
| MGNX - MacroGenics Inc | BUY | 1,605 @ USD 1.42 | USD 2,279 | The ETF bought 1605 new shares of MGNX (MacroGenics Inc). The shares were bought for an average price of 1.42 compared to the previous average buy price of 1.56668. This is -9.4% lower than average price of previous purchases of MGNX. |
| PLRX - Pliant Therapeutics Inc | BUY | 1,500 @ USD 1.49001 | USD 2,235 | The ETF bought 1500 new shares of PLRX (Pliant Therapeutics Inc). The shares were bought for an average price of 1.49001 compared to the previous average buy price of 1.51183. This is -1.4% lower than average price of previous purchases of PLRX. |
| BMEA - Biomea Fusion Inc | BUY | 1,800 @ USD 0.957306 | USD 1,723 | The ETF bought 1800 new shares of BMEA (Biomea Fusion Inc). The shares were bought for an average price of 0.957306 compared to the previous average buy price of 1.66943. This is -42.7% lower than average price of previous purchases of BMEA. |
| OKUR - OKUR | BUY | 315 @ USD 2.62 | USD 825 | The ETF bought 315 new shares of OKUR (OKUR). The shares were bought for an average price of 2.62 compared to the previous average buy price of 5.96367. This is -56.1% lower than average price of previous purchases of OKUR. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| CVAC - CureVac NV | HOLD | 0 @ USD 5.11 | USD 0 | The current share valuation price of CVAC based on adjusted close was USD 5.11. The average price that CVAC shares were previous bought at was USD 4.87431. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in CVAC has fallen by USD 13,590 compared to the previous valuation of CureVac NV |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 15.86 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 15.86. The average price that JANX shares were previous bought at was USD 28.0942. The current market price is -43.5% lower than average price they were purchased at. The value of the holding in JANX has fallen by USD 729,805 compared to the previous valuation of Janux Therapeutics Inc |
| STRO - Sutro Biopharma | HOLD | 0 @ USD 0.729792 | USD 0 | The current share valuation price of STRO based on adjusted close was USD 0.729792. The average price that STRO shares were previous bought at was USD 0.899783. The current market price is -18.9% lower than average price they were purchased at. The value of the holding in STRO has fallen by USD 3,801 compared to the previous valuation of Sutro Biopharma |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-12-02 this would crystalise an overall loss. |